Arnab K Chatterjee

List of Publications by Citations

66 papers	4,847 citations	37 h-index	69 g-index
71 ext. papers	5,889 ext. citations	11.5 avg, IF	4.95 L-index

#	Paper	IF	Citations
66	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. *Nature*, **2020**, 586, 113-119	50.4	405
65	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 9059-64	11.5	361
64	Targeting Plasmodium PI(4)K to eliminate malaria. *Nature*, **2013**, 504, 248-253	50.4	291
63	Decarboxylative borylation. *Science*, **2017**, 356,	33.3	244
62	Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. *Science*, **2011**, 334, 1372-7	33.3	243
61	Antimalarial drug discovery - approaches and progress towards new medicines. *Nature Reviews Microbiology*, **2013**, 11, 849-62	22.2	202
60	Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4453-8	11.5	190
59	A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. *Nature Communications*, **2010**, 1, 57	17.4	190
58	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. *Nature Chemical Biology*, **2008**, 4, 347-56	11.7	178
57	Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2510-7	11.5	150
56	A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. *Nature*, **2018**, 562, 600-604	50.4	116
55	A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. *ACS Chemical Biology*, **2012**, 7, 1190-7	4.9	109
54	Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. *Science Translational Medicine*, **2013**, 5, 214ra168	17.5	105
53	KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 5060-7	5.9	101
52	The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10750-10755	11.5	97
51	Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. *Science*, **2020**, 369, 993-999	33.3	94
50	Imidazolopiperazines: hit to lead optimization of new antimalarial agents. *Journal of Medicinal Chemistry*, **2011**, 54, 5116-30	8.3	88

49	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. *Nature Communications*, **2014**, 5, 5521	17.4	85
48	Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. *Journal of Medicinal Chemistry*, **2012**, 55, 4244-73	8.3	75
47	Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. *Journal of Medicinal Chemistry*, **2013**, 56, 8849-59	8.3	68
46	A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005373	4.8	68
45	Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. *Molecular and Biochemical Parasitology*, **2011**, 175, 21-9	1.9	62
44	Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. *ACS Chemical Biology*, **2015**, 10, 413-20	4.9	57
43	Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. *Journal of Medicinal Chemistry*, **2014**, 57, 828-35	8.3	57
42	KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 1586-95	5.9	56
41	Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10282-7	11.5	55
40	Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19 **2021**,		53
39	Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1975-80	2.9	50
38	Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 6834-6839	11.5	44
37	Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs. *Cell Chemical Biology*, **2018**, 25, 1086-1094.e7	8.2	44
36	Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4679-4684	11.5	42
35	Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. *Current Topics in Medicinal Chemistry*, **2012**, 12, 473-83	3	41
34	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals **2020**,		40
33	Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6920-E6926	11.5	39
32	Targeted Disruption of Myc-Max Oncoprotein Complex by a Small Molecule. *ACS Chemical Biology*, **2017**, 12, 2715-2719	4.9	38

31	Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate. *Bioconjugate Chemistry*, **2015**, 26, 2216-22	6.3	37
30	Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. *PLoS Pathogens*, **2015**, 11, e1005058	7.6	37
29	Road towards new antimalarials - overview of the strategies and their chemical progress. *Current Medicinal Chemistry*, **2011**, 18, 853-71	4.3	32
28	Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. *ACS Medicinal Chemistry Letters*, **2013**, 4, 451-5	4.3	30
27	2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles. *Journal of the American Chemical Society*, **2020**, 142, 8972-8979	16.4	30
26	Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. *Angewandte Chemie - International Edition*, **2018**, 57, 3478-3482	16.4	28
25	Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5112-7	2.9	28
24	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. *Nature Communications*, **2021**, 12, 3309	17.4	25
23	Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. *ACS Medicinal Chemistry Letters*, **2014**, 5, 947-50	4.3	24
22	Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. *Angewandte Chemie - International Edition*, **2017**, 56, 13011-13015	16.4	24
21	The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors. *Antiviral Research*, **2019**, 169, 104558	10.8	23
20	Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5255-8	2.9	23
19	Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections. *Science Translational Medicine*, **2019**, 11,	17.5	22
18	Lead identification to clinical candidate selection: drugs for Chagas disease. *Journal of Biomolecular Screening*, **2015**, 20, 101-11		22
17	Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4027-31	2.9	22
16	Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 11501-11506	11.5	22
15	Neratinib protects pancreatic beta cells in diabetes. *Nature Communications*, **2019**, 10, 5015	17.4	21
14	Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5107-11	2.9	21

13	Small molecule selectively suppresses MYC transcription in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3497-3502	11.5	20
12	Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5895-9	2.9	18
11	Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK). *Journal of Medicinal Chemistry*, **2013**, 56, 7741-9	8.3	17
10	Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases. *FASEB Journal*, **2016**, 30, 2570-9	0.9	16
9	Cell-based optimization of novel benzamides as potential antimalarial leads. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6970-4	2.9	15
8	Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1486-90	2.9	15
7	Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 2899-903	2.9	13
6	Discovery of highly potent, lung-localized epithelial sodium channel inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4797-4801	2.9	11
5	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19		10
4	Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment. *Journal of the American Chemical Society*, **2021**, 143, 13044-13055	16.4	9
3	YAP-dependent proliferation by a small molecule targeting annexin A2. *Nature Chemical Biology*, **2021**, 17, 767-775	11.7	6
2	Discovery and SAR studies of 3-amino-4-(phenylsulfonyl)tetrahydrothiophene 1,1-dioxides as non-electrophilic antioxidant response element (ARE) activators. *Bioorganic Chemistry*, **2021**, 108, 104614	5.1	2
1	Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. *Angewandte Chemie*, **2017**, 129, 13191-13195	3.6	0